Evidence map›Paper›PMID 32610574›Full record

ArticleInternational journal of molecular sciences2020

Effects of Apigenin on RBL-2H3, RAW264.7, and HaCaT Cells: Anti-Allergic, Anti-Inflammatory, and Skin-Protective Activities.

Che-Hwon Park, Seon-Young Min, Hye-Won Yu, Kyungmin Kim, Suyeong Kim, Hye-Ja Lee, Ji-Hye Kim, Young-Jin Park

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. In Vitro Bioactivity of a Supercritical COMolecules (Basel, Switzerland) · 2026
    Article
  6. Review
  7. Food science & nutrition · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Frontiers in veterinary science · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Phytochemical Analysis and Phytometabolomic Profiling ofInternational journal of molecular sciences · 2025
    Article
  20. In Vitro Characterization ofInternational journal of molecular sciences · 2025
    Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Che-Hwon ParkDepartment of Medicinal Biosciences, Research Institute for Biomedical & Health Science, College of Biomedical and Health Science, Konkuk University, 268 Chungwon-daero Chungju-si 27478, Korea.
Seon-Young MinDepartment of Medicinal Biosciences, Research Institute for Biomedical & Health Science, College of Biomedical and Health Science, Konkuk University, 268 Chungwon-daero Chungju-si 27478, Korea.
Hye-Won YuDepartment of Medicinal Biosciences, Research Institute for Biomedical & Health Science, College of Biomedical and Health Science, Konkuk University, 268 Chungwon-daero Chungju-si 27478, Korea.
Kyungmin KimJeju R&D Center, AMI Cosmetics Co., Ltd., 16, Sancheondandong-gil, Jeju-si 63359, Korea.
Suyeong KimJeju R&D Center, AMI Cosmetics Co., Ltd., 16, Sancheondandong-gil, Jeju-si 63359, Korea.
Hye-Ja LeeNatural Products Laboratory, DAEBONG Life Science Co., Ltd., 213-4, Chumdan-Ro, Jeju-si 63309, Korea.
Ji-Hye KimNatural Products Laboratory, DAEBONG Life Science Co., Ltd., 213-4, Chumdan-Ro, Jeju-si 63309, Korea.
Young-Jin ParkDepartment of Medicinal Biosciences, Research Institute for Biomedical & Health Science, College of Biomedical and Health Science, Konkuk University, 268 Chungwon-daero Chungju-si 27478, Korea.
Konkuk University · KR

Funding

The Ministry of Trade, Industry & Energy(MOTIE), Korea Institute for Advancement of Technology(KIAT) P0002201
6 · The paper itself

Abstract

Apigenin (4',5,7-trihydroxyflavone, flavonoid) is a phenolic compound that is known to reduce the risk of chronic disease owing to its low toxicity. The first study on apigenin analyzed its effect on histamine release in the 1950s. Since then, anti-mutation and antitumor properties of apigenin have been widely reported. In the present study, we evaluated the apigenin-mediated amelioration of skin disease and investigated its applicability as a functional ingredient, especially in cosmetics. The effect of apigenin on RAW264.7 (murine macrophage), RBL-2H3 (rat basophilic leukemia), and HaCaT (human immortalized keratinocyte) cells were analyzed. Apigenin (100 μM) significantly inhibited nitric oxide (NO) production, cytokine expression (interleukin (IL)-1β, IL6, cyclooxygenase (COX)-2, and inducible nitric oxide synthase [iNOS]), and phosphorylation of mitogen-activated protein kinase (MAPK) signal molecules, including extracellular signal-regulated kinase (ERK) and c-Jun N-terminal protein kinase (JNK) in RAW264.7 cells. Apigenin (30 M) also inhibited the phosphorylation of signaling molecules (Lyn, Syk, phospholipase Cγ1, ERK, and JNK) and the expression of high-affinity IgE receptor FcεRIα and cytokines (tumor necrosis factor (TNF)-α, IL-4, IL-5, IL-6, IL-13, and COX-2) that are known to induce inflammation and allergic responses in RBL-2H3 cells. Further, apigenin (20 μM) significantly induced the expression of filaggrin, loricrin, aquaporin-3, hyaluronic acid, hyaluronic acid synthase (HAS)-1, HAS-2, and HAS-3 in HaCaT cells that are the main components of the physical barrier of the skin. Moreover, it promoted the expression of human β-defensin (HBD)-1, HBD-2, HBD-3, and cathelicidin (LL-37) in HaCaT cells. These antimicrobial peptides are known to play an important role in the skin as chemical barriers. Apigenin significantly suppressed the inflammatory and allergic responses of RAW264.7 and RBL cells, respectively, and would, therefore, serve as a potential prophylactic and therapeutic agent for immune-related diseases. Apigenin could also be used to improve the functions of the physical and chemical skin barriers and to alleviate psoriasis, acne, and atopic dermatitis.

Indexed as

AnimalsAnti-Allergic AgentsAnti-Inflammatory AgentsApigeninCell LineCytokinesExtracellular Signal-Regulated MAP KinasesFilaggrin ProteinsHaCaT CellsHumansImmunoglobulin EInterleukin-1betaJNK Mitogen-Activated Protein KinasesMast CellsMiceNitric OxideAnti-Allergic AgentsAnti-Inflammatory AgentsApigeninCytokinesExtracellular Signal-Regulated MAP KinasesFilaggrin ProteinsFLG protein, humanIL1B protein, humanImmunoglobulin EInterleukin-1betaJNK Mitogen-Activated Protein KinasesNitric OxideNitric Oxide Synthase Type IINOS2 protein, humanReceptors, IgETumor Necrosis Factor-alphaanti-allergyanti-inflammationapigeninflavoneHaCaTRAW264.7RBL-2H3

Identifiers

PMID32610574
PMCPMC7370139
OpenAlexW3037695303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.